The Authors' Reply to "How to Demonstrate the Impact of Dapagliflozin on Improving Hyperuricemia in Patients with Chronic Kidney Disease".

Mori, Daisuke; Kobayashi, Midori; Wada, Masafumi; Tokuchi, Maho; Misegawa, Soichiro; Saito, Rina; Nomi, Hiroki; Haga, Ryota; Nagatoya, Katsuyuki; Yamauchi, Atsushi

Mori, Daisuke; Kobayashi, Midori; Wada, Masafumi; Tokuchi, Maho; Misegawa, Soichiro; Saito, Rina; Nomi, Hiroki; Haga, Ryota; Nagatoya, Katsuyuki; Yamauchi, Atsushi.

Affiliation

Mori D; Department of Nephrology, Osaka Rosai Hospital, Japan.
Kobayashi M; Department of Nephrology, Osaka Rosai Hospital, Japan.
Wada M; Department of Nephrology, Osaka Rosai Hospital, Japan.
Tokuchi M; Department of Nephrology, Osaka Rosai Hospital, Japan.
Misegawa S; Department of Nephrology, Osaka Rosai Hospital, Japan.
Saito R; Department of Nephrology, Osaka Rosai Hospital, Japan.
Nomi H; Department of Nephrology, Osaka Rosai Hospital, Japan.
Haga R; Department of Nephrology, Osaka Rosai Hospital, Japan.
Nagatoya K; Department of Nephrology, Osaka Rosai Hospital, Japan.
Yamauchi A; Department of Nephrology, Osaka Rosai Hospital, Japan.

Intern Med ; 63(15): 2229-2230, 2024 Aug 01.

Article in En | MEDLINE | ID: mdl-38171866

Subject(s)
Key words

advanced CKD; dapagliflozin; uric acid

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Benzhydryl Compounds / Hyperuricemia / Renal Insufficiency, Chronic / Sodium-Glucose Transporter 2 Inhibitors / Glucosides Limits: Humans Language: En Journal: Intern Med / Intern. med. (Tokyo) / Internal medicine (Tokyo) Journal subject: MEDICINA INTERNA Year: 2024 Document type: Article Affiliation country: Japón Country of publication: Japón

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google